Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients
Authors:
- Virginia ChiocchiaVCVirginia Chiocchia
- Susan DuttonSDSusan Dutton
- Aakash PaiAPAakash Pai
- Benjamin E. AyresBABenjamin E. Ayres
- Pieter Le RouxPRPieter Le Roux
- Michael SwinnMSMichael Swinn
- Michael BaileyMBMichael Bailey
- Matthew J.A. PerryMPMatthew J.A. Perry
- Rami IssaRIRami Issa
- 6 August 2015
- journal article
- research article
- Published by S. Karger AG in Urologia Internationalis
- Vol. 96 (1) , 83-90
Abstract
Introduction: Hyperthermic mitomycin (HM) is a novel treatment modality for selected patients with high-risk non-muscle invasive bladder cancer (NMIBC). We sought to determine predictors of response to this therapy. Patients and Methods: A longitudinal, cohort study of 97 patients with high-risk NMIBC treated with ≥4 HM instillations on a prophylactic schedule was conducted. The primary outcome was time-to-progression survival; secondary outcomes were overall survival, cancer-specific survival, and adverse events. Descriptive statistics, Kaplan-Meier survival analyses, Cox proportional hazards modelling, and univariate and multivariable regression were performed. Results: The presence of initial complete response (CR; no evidence of disease at first check video-cystoscopy and urine cytology) post-HM treatment was an independent predictor of good response to HM. Female patients and those without carcinoma in situ (CIS) also appeared to respond better to the intervention. The overall bladder preservation rate at a median of 27 months was 81.4%; 17/97 (17.5%) patients died during the course of the study. Conclusions: High-risk NMIBC patients can be safely treated with HM and have good oncological outcome. However, those without an initial CR have a poor prognosis and should be counselled towards adopting other treatment methodologies such as cystectomy. Female gender and lack of CIS may be good prognostic indicators for response to HM.Keywords
This publication has 27 references indexed in Scilit:
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013European Urology, 2013
- Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-GuerinJournal of Urology, 2009
- EFFECT OF HYPERTHERMIA ON THE CYTOTOXICITY OF 4 CHEMOTHERAPEUTIC AGENTS CURRENTLY USED FOR THE TREATMENT OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER: AN IN VITRO STUDYJournal of Urology, 2005
- Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patientsAnnals of Oncology, 2005
- Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the BladderEuropean Urology, 2004
- Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell CarcinomaJournal of Clinical Oncology, 2003
- Complications of Radical Cystectomy For Nonmuscle Invasive Disease: Comparison With Muscle Invasive DiseaseJournal of Urology, 2003
- Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinomaBritish Journal of Clinical Pharmacology, 2001
- LOCAL MICROWAVE HYPERTHERMIA AND INTRAVESICAL CHEMOTHERAPY AS BLADDER SPARING TREATMENT FOR SELECT MULTIFOCAL AND UNRESECTABLE SUPERFICIAL BLADDER TUMORSJournal of Urology, 1998
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987